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Abstract
Background: The risk of exacerbation in chronic obstructive pulmonary disease (COPD) depends on the severity of
disease and other less well known factors. Predictive models of exacerbation are more accurate than the forced
expiratory volume in one second (FEV1). The objective was to design a model that predicts the risk of exacerbation
in COPD.
Methods: Retrospective cohort study with data from the electronic medical records of patients diagnosed with
COPD in the province of Lleida (Spain). A total of 2501 patients were followed during 3 years. The dependent variable
was acute exacerbation; independent variables were: clinical parameters, spirometry results, severity of disease, influenza
and 23-valent pneumococcal immunisation, comorbidities, smoking and history of exacerbation. The association of these
variables with disease exacerbation was measured by the adjusted odds ratio using a logistic regression model.
Results: Mean age at the start of the study was 68.38 years (SD = 11.60) and 74.97 % patients were men; severity of
disease was considered mild in 50.82 % of patients, moderate in 35.31 %, severe in 9.44 % and very severe in 4.44 %.
During the three year study period up to 83.17 % of patients experienced at least one exacerbation. Predictive factors in
the model were age, gender, previous exacerbations, influenza and 23-valent pneumococcal immunisations, number of
previous visits to the General Practice and severity (GOLD), with an area under the ROC curve (AUROC) of 0.70.
Conclusions: This model can identify patients at high risk of acute exacerbation. Preventive measures and modification of
treatment in these high-risk patients would improve survival.
Keywords: Chronic obstructive pulmonary disease (COPD), Risk factors, Acute disease
Background
The global burden of chronic obstructive pulmonary dis-
ease (COPD) is high [1]. Some patients with COPD experi-
ence three episodes of acute exacerbation per year on
average [2]. Most acute exacerbation episodes require med-
ical attention, either in primary care or in hospital [3].
Predictive factors of exacerbation are still not completely
understood [4–9]. However, acute exacerbations are known
to accelerate the severity of disease, [3] contribute to irre-
versible decline of pulmonary function [10], have a negative
impact on quality of life [11] and decrease survival [12].
The proportion of treatment failure in patients with acute
exacerbations is high (20–40 %) [13] and it is associated
with elevated health costs [14].
Traditionally, a decrease in forced expiratory volume in
one second (FEV1) has been considered one of the main
risk factors of exacerbation. However, FEV1 does not dis-
criminate between stable periods of disease and acute exac-
erbations, and is less effective in the late stages of the
disease [3]. Indeed, some patients with low FEV1 have never
experienced acute exacerbations, and a higher FEV1 does
not rule out the risk of exacerbation [15].
It is essential to consider COPD as a systemic disease
rather than just pulmonary, since it is associated with
symptoms in other organs and with comorbidities [16, 17]
that can determine the risk of acute exacerbation. Conse-
quently, new multifactorial predictive models for exacerba-
tion are required [18]. The BODE index, which comprises
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Body Mass Index, airflow Obstruction, Dyspnoea and Exer-
cise (distance walked in 6 min) is a predictive factor of mor-
tality in COPD and a better predictive factor for acute
exacerbation than FEV1 [19]. The study of Marin et al.
showed that the BODE index was a better predictive
method than FEV1 for acute exacerbation in patients with
COPD [19]. However, the six minute walk test is not easily
implemented in primary care. Other models have been pro-
posed [20–22]. Nonetheless, new models with variables that
can be obtained easily and quickly are needed.
Factors related to acute exacerbation are still poorly
understood [5]. Some variables have been identified with
risk of exacerbation. However, further studies are needed
to prove the association of these factors with acute ex-
acerbation and to validate models of prediction [23].
Factors such as the characteristics of the population,
prevalence of risk factors, severity of COPD and aspects of
the health system [3] result in a geographical variation in
the incidence of exacerbation [24]. In consequence, predict-
ive models should be adjusted to different settings.
The objective of this study was to determine predictive
factors associated with exacerbation of COPD in a pri-
mary care cohort of patients in Catalonia (Spain) with a
high percentage of mild and moderate severity during a
three year follow up.
Methods
A retrospective cohort study was carried out with 2501 pa-
tients with a COPD diagnosis from seven primary care cen-
tres of the Lleida Health Region (catchment population:
172,950). The criteria of inclusion were over 40 years of age
with a diagnosis of COPD in 2010 in primary care elec-
tronic medical records and having a spirometry test in the
last two years. GOLD criteria were followed for the diagno-
sis of COPD: [25] a post bronchodilator FEV1/FVC <0.7
when the patient is in the stable phase of the disease. For a
patient to be included in the study, the electronic medical
records must also contain the result of a spirometry test
from the previous 2 years. The dependent variable was
acute exacerbation of COPD, defined as an increase in dys-
pnoea, amount and purulence of sputum [26] that require
treatment with systemic steroids and/or antibiotics (moder-
ate exacerbations) or that require hospitalization (severe ex-
acerbations) [27]. The referral hospitals were the University
Hospital Arnau de Vilanova and the Hospital Santa Maria
de Lleida. These were the two hospitals where the patients
that required admission were referred. Exacerbations be-
tween November 2010 and October 2013 were computed.
Data sources were the primary care electronic medical re-
cords (e-CAP) and the Health Department Pharmacy Unit
Register. The following independent variables were col-
lected at the beginning of the study: age, gender, spirometry
results (FEV1/CVF, FVC, FEV1), comorbidities (heart fail-
ure, ischemic heart disease, diabetes, chronic kidney failure,
atrial fibrillation and anaemia), history of smoking, 23-
valent pneumococcal and influenza immunisations for the
2009/10 season, years since COPD was diagnosed, number
of visits to the health centre and number of acute exacerba-
tions in the year prior to the start of the study, and COPD
severity according to the GOLD Guidelines.
This study was approved by the Clinical Research Ethics
Committee of the Primary Care Research Institute (IDIAP)
Jordi Gol of Barcelona (P14/022). This ethics committee
determined that individual patient consent was not neces-
sary due to the retrospective nature of the study. We also
obtained the consent by management of all the seven pri-
mary care centres participating in the study (Lleida, Pla
d’Urgell, Les Borges Blanques, Bellpuig, Tàrrega, Agramunt
and Cervera) as well as the approval by the management of
Primary Care of the Healthcare Region of Lleida. The Pri-
mary Care Management of the Catalan Institute of Health
authorized permission to access the clinical records of the
patients included in the study with the ultimate aim of
gathering information concerning the variables of interest.
Statistical analysis
A descriptive analysis of the data was performed. Quantita-
tive variables were described using the mean and standard
deviation and categorical variables using the absolute and
relative frequencies. Hypothesis testing to evaluate the asso-
ciation of independent variables with the clinical outcome
(COPD exacerbation) was performed using the Chi-square
test for categorical variables and Student’s t test or Mann-
Whitney’s U test for continuous variables. The crude odds
ratio (OR) was calculated for each independent variable in-
cluded in the model.
A derivation cohort (70 %) and a validation cohort
(30 %) were randomly generated. The score was adjusted
in the derivation cohort and the predicted probability,
power and calibration were estimated from the 30 % in-
cluded in the validation cohort. The score included all var-
iables associated with an outcome with a P value <0.2.
The risk score was adjusted for the 3-year period with a
logistic regression analysis using automatic (forward and
backward) variable selection algorithms. Selected variables
were included in the model if the P value of the effect was
<0.1. The characteristics of the calibration were evaluated
by the Hosmer-Lemeshow test and the discriminatory
power using the c- statistic of the area under the curve
(AUC).
Statistical Interaction and quadratic effect were tested
for all quantitative variables. Statistical significance was
considered if P-value <0.05. All analyses were performed
using the statistical package SPSS v15.0.
Results
Mean age of the 2501 patients at the start of the study was
68.38 years (SD = 11.60) and 75 % were men. Severity of
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disease (GOLD) was mild in 50.82 % patients, moderate in
35.31 %, severe in 9.44 % and very severe in 4.44 %. The
year prior to the start of the study a total of 20.23 % pa-
tients had experienced at least one episode of acute exacer-
bation and the average number of visits to the physician or
nurse in primary care was 25. With regard to immunisa-
tion, 70.45 % had received the 23-valent pneumococcal vac-
cine and 71.41 % the influenza vaccine during the 2009/10
season (season prior to the start of the study).
Table 1 shows the characteristics of the patients in rela-
tion to acute exacerbations. Patients who experienced acute
exacerbations were older, had attended the primary care
centre more often during 2009, presented more comorbidi-
ties (heart failure, ischemic heart disease, diabetes, chronic
kidney failure, atrial fibrillation and anaemia) and had expe-
rienced more acute exacerbations during the year prior to
the start of the study. Up to 83.17 % of patients experienced
at least one episode of acute exacerbation during the 3-year
follow up. Patients with a higher severity of disease (GOLD
grades III and IV) experienced higher rates of acute exacer-
bation (Table 2), and had higher rates of immunisation with
the 23-valent pneumococcal and influenza vaccines during
the 2009/2010 season (p <0.001).
The multivariate analysis (Table 3) shows that the follow-
ing factors are significantly associated with COPD exacer-
bation: age (mean 68 years (aOR = 1.01), gender (woman)
(aOR = 1.46), gender (woman) x age (mean 68 years (aOR =
0.96), previous exacerbations (aOR = 7.44), severe or very
severe disease (GOLD), (aOR = 1.57), number of visits to
the primary care centre (from 25 to 50 visits (aOR = 1.64);
over 50 visits (aOR = 2.95) in relation to the standard (<25
visits), influenza vaccine (aOR = 2.00), 23-valent pneumo-
coccal vaccine (aOR = 1.82), influenza x 23-valent pneumo-
coccal vaccine (aOR = 0.46). Patients immunised with the
pneumococcal and influenza vaccines had a 54 % lower risk
of exacerbation. All these variables were significantly associ-
ated with COPD exacerbation, with a discriminatory power
of 0.71. Fig. 1 shows the calibration and discriminatory
power of the predictive model. The predictive factor more
strongly associated with disease exacerbation was acute ex-
acerbation during the year prior to the start of the study,
which increased the risk of experiencing acute exacerbation
by 7.44 during the following 3 years.
Discussion
In this study, patients with at least one episode of exacerba-
tion during the 3-year follow-up were older and more often
men; they had a higher COPD severity grade (GOLD III
and IV), they had experienced more acute exacerbation epi-
sodes during the year prior to the study and had attended
the primary care centre more often due to a higher preva-
lence of comorbidities. Older patients experienced a higher
Table 1 Characteristics of patients at the beginning of the study and description of variables associated with acute exacerbation
during the 3-year follow-up
Exacerbation (treatment during next 3y) All (n = 2501)
No (n = 421) Yes (n = 2080) p
Agea 65.62 (11.90) 68.94 (11.50) 0.001 68.38 (11.60)
COPD History (years)a 2.86 (3.50) 3.69 (4.40) 0.001 3.55 (4.30)
Num. of visits (2009)a 18.01 (14.30) 25.96 (18.70) 0.001 24.63 (18.30)
FEV1 66.38 (23.20) 62.80 (24.40) 0.004 63.38 (24.30)
Gender (female)b 79 (18.76 %) 547 (26.30 %) 0.001 626 (25.03 %)
23-valent Pneumococcalb 242 (57.48 %) 1520 (73.08 %) 0.001 1762 (70.45 %)
2009 influenza vaccineb 242 (57.48 %) 1544 (74.23 %) 0.001 1786 (71.41 %)
Exacerbation 2009b 20 (4.75 %) 486 (23.37 %) 0.001 506 (20.23 %)
Number of comorbiditiesc 0.34 (0.70) 0.45 (0.70) 0.002 0.43 (0.70)
Smokingb 178 (42.28 %) 666 (32.02 %) 0.001 844 (33.75 %)
Gold (Severity)b 0.062
Mild COPD 223 (52.97 %) 1048 (50.38 %) 1271 (50.82 %)
Moderate COPD 157 (37.29 %) 726 (34.90 %) 883 (35.31 %)
Severe COPD 27 (6.41 %) 209 (10.05 %) 236 (9.44 %)
Very Severe COPD 14 (3.33 %) 97 (4.66 %) 111 (4.44 %)
Hospital Admissionb 62 (14.73 %) 750 (36.06 %) 0.001 812 (32.47 %)
Deathb 39 (9.26 %) 275 (13.22 %) 0,025 314 (12.55 %)
amean (SD): Mann–Whitney U test
babsolute and relative frequency. Chi-square test
cNumber of comorbidities: Ischemic Heart Disease, Heart Failure, Diabetes, Anaemia, Atrial Fibrillation and Chronic Renal Failure
The statistical significance is fixed for p-value <0.05
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rate of acute exacerbation episodes, probably because pul-
monary function decreases with time and because of the
accumulative effect of risk factors such as smoking. On the
other hand, this study confirms the effectiveness of the in-
fluenza and 23-valent pneumococcal vaccines. Indeed, im-
munisation reduces risk practically by half. This model
could be used in primary care visits to identify patients with
a higher risk of exacerbation.
Interpretation of results based on the literature
Other authors have researched similar predictive models
for exacerbation, with slight differences. Miravitlles et al.
[28] designed a model for exacerbation with the follow-
ing variables: age, FEV1 (GOLD severity) and chronic
sputum production, and obtained an area under the
ROC curve (AUROC) of 0.601 . Our model also includes
age and FEV1, though it achieves a higher discriminatory
power. Motegi et al. [29] compared three predictive
models of COPD exacerbation: the DOSE (dyspnoea, de-
gree of airflow limitation, smoking and exacerbations);
BODE (body mass index, degree of airflow limitation,
dyspnoea and exacerbations); and ADO (age, dyspnoea,
degree of airflow limitation) indices. These predictive
models had a discriminatory power (ROC curve) of 0.75,
0.65 and 0.64, respectively. The authors concluded that
the best model to predict future exacerbations in COPD
patients was the DOSE index. Our model has a higher
AUROC than those found by Motegi et al. for the BODE
and ADO indices, and it also contains risk factors com-
mon to the three models: age, degree of airflow limita-
tion and history of exacerbation. Make et al. [20]
developed a score (SCOPEX) that included variables
such as gender, number of COPD maintenance medica-
tions, number of exacerbations in the previous year,
FEV1/FVC and number of daily short-acting bronchodi-
lators for clinicians to predict exacerbations. Moberg
Table 2 Immunisation and acute exacerbation in relation to severity of COPD
Mild Moderate Severe Very Severe All p
(n = 1271) (n = 883) (n = 236) (n = 111) (n = 2501)
23-valent Pneumococcala 866 (68.14 %) 628 (71.12 %) 185 (78.39 %) 83 (74.77 %) 1762 (70.45 %) 0.002
2009influenza vaccinea 880 (69.24 %) 636 (72.03 %) 183 (77.54 %) 87 (78.38 %) 1786 (71.41 %) 0.002
Exacerbation (treatment during next 3y or hospital admission)a 1048 (82.45 %) 726 (82.22 %) 209 (88.56 %) 97 (87.39 %) 2080 (83.17 %) 0.043
aAbsolute and relative frequency. Chi-square test
Table 3 Predictive factors of COPD exacerbation during the 3-year follow-up period
Exacerbation (treatment in next 3y)
OR 95 % CI p
Num. Of visits 2009 (Standard < 25v) 0.001
25–50 1.64 (1.17 – 2.29) 0.004
> 50 2.95 (1.25 – 6.94) 0.013
Gender (female) 1.46 (1.04 – 2.04) 0.028
Exacerbation 7.44 (3.77 – 14.70) 0.001
INT: Female * Age (mean 68y) 0.96 (0.93 – 0.99) 0.003
Age (mean 68y) 1.01 (1,00 – 1.03) 0.087
Gold severity grade (severe or very severe) 1.57 (1.01 – 2.45) 0.046
2009 influenza vaccine 2.00 (1.12 – 3.58) 0.019
23-valent Pneumococcal vaccine 1.82 (1.00 – 3.29) 0.049
INT: 2009 influenza vaccine * Pneumococcal 0.46 (0.20 - 1.02) 0.055
Derivation
Hosmer & Lemeshow 1.10 0.997
AUC ROC 0.71 (0.68 – 0.74) < 0.001
Validation
Hosmer & Lemeshow 41.00 <0.001
AUC ROC 0.69 (0.64 – 0.74) <0.001
INT Interaction
OR odds ratio
OR was adjusted for: Num. of visits, gender, exacerbation, GOLD severity grade, influenza vaccine, 23-valent pneumococcal vaccine
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et al. [21] used measures of exercise capacity and dys-
pnoea scores to develop the iBODE index as a predictor.
While Schembri et al. [22] also developed a predictive
model based on data collected from clinic visits on dem-
ography, spirometry, smoking history, dyspnoea score,
BMI and other variables.
In our model, a history of exacerbation is the best pre-
dictive factor for exacerbation, followed by an age over
68. The study by Hurst et al. also concluded that a his-
tory of exacerbation during the previous year was the
best predictive factor of acute exacerbation [27].
As in other studies, the male sex was a risk factor of
exacerbation due to the smoking habits. However, other
studies have reported a higher risk of exacerbation in
females [30].
Our study further supports the evidence on the effective-
ness of influenza and 23-valent pneumococcal immunisa-
tions in significantly reducing the risk of acute exacerbation
[31, 32]. This study contributes a new predictive model of
COPD exacerbation with variables that are easily and
swiftly collected. The high discriminatory power makes this
model adequate for use in primary care.
Strengths and limitations of the study
The main strengths of the study are the length of the
follow-up period (3 years) and characteristics of the cohort
(the sample consists of a high percentage of patients with
mild and moderate severity, unlike other studies, thus, our
sample is more representative of the spectrum of the dis-
ease in the community. The primary care electronic
medical records include all patients with a diagnosis of
COPD in our region. In contrast, hospitals registers only in-
clude patients with the most severe forms of the disease.
The study has also some limitations. The information was
obtained from primary care electronic medical records,
where some variables such as smoking and influenza and
pneumococcal immunisations can be underreported. Some
series like the UPLIFT studies found a prevalence of 29 %
of smokers, [33] whereas another reports a prevalence as
low as 4.4 % [6], much less than our study.
The study included patients with a diagnosis of COPD
and with a spirometry result from 2 years prior to the start
of the study. These inclusion criteria ensure that all patients
were correctly diagnosed, but might exclude patients with
COPD either because of underreporting or because they
did not have a spirometry result in their electronic medical
records. Such patients would probably be those with a mild
disease. Also, patients were considered immunised against
influenza or pneumococcal disease only when the immun-
isation was registered in the eCAP. When patients are
immunised in private clinics it might not be adequately re-
corded. Some patients may give up smoking after the study
and this change was not registered. Consequently, the ef-
fects of smoking and the protective effect of immunization
might be underestimated. With regard to influenza immun-
isation, we only considered the 2009/10 seasonal immun-
isation. However, immunised patients tend to attend
immunisations every year [34] and thus those immunised
during the 2009/10 season were probably also immunised
during the following seasons. Some variables studied in
Fig. 1 Exacerbation ROC curve after 3 years of follow up (validation and derivation cohorts)
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other models, such as weight/BMI, exercise/functional cap-
acity or dyspnoea, were not investigated due to a lack of
comprehensive information for all patients. Lastly, we must
highlight that the predictors objectified in this study may
vary depending on the geographical area of the study and
the characteristics of health systems specific for each one,
which is why more studies are needed in different health
regions.
Implications for future research and practice
Some risk factors might vary in different settings. Other
variables should be investigated in other future models and
in other places, like the number of medication [20], season-
ality [35, 36], sleep disturbance[37] and exposure to pollut-
ants [38, 39]. Our study reports risk factors of COPD
exacerbation in a specific region of Spain. External valid-
ation of this predictive model is required before implement-
ing it in other cohorts of patients with COPD.
Conclusions
This predictive model of acute exacerbation in COPD can
be easily and quickly implemented in primary care. Patients
at high risk could be identified for preventive action, such
as immunisation and for intensification of treatment. As a
consequence, quality of life and survival rates in patients
with COPD would improve.
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